微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 21.61% | -52.43% | -31.31% | 130/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 31.46% | -32.74% | -36.55% | 113/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 49.59% | 24.8% | 29.64% | 68/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 38.25% | -17.18% | -15.81% | 106/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 45.43% | -10.81% | -2.87% | 87/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 46.78% | -11.77% | 17.72% | 86/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 39.74% | -25.87% | -13.97% | 94/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.19% | -13.62% | -9.34% | 91/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 50.94% | -15.36% | -3.91% | 73/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 53.02% | -15.08% | -1.1% | 70/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 53.6% | -11.34% | 0.26% | 71/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 53.47% | -19.26% | -11.17% | 76/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 60.19% | -11.92% | -3.59% | 54/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 62.43% | -10.02% | 3.26% | 53/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 60.46% | -10.41% | -8.7% | 56/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 66.22% | 3.28% | -3.09% | 50/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 68.33% | -11.44% | -1.51% | 38/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 69.38% | -9.62% | 2.81% | 38/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 67.48% | -18.34% | 5.25% | 34/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 64.12% | -13.65% | -16.91% | 50/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 77.16% | 1.21% | 0.51% | 22/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 76.76% | -1.08% | -7.1% | 21/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 82.64% | 29.46% | 11.29% | 13/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 74.25% | 30.91% | -2.6% | 28/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 76.24% | 35.19% | -1.76% | 17/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 77.61% | 34.12% | 21.58% | 19/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 63.83% | 30.37% | 12.53% | 35/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 56.72% | 1.07% | 0.59% | 63/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 56.39% | -19.43% | -2.54% | 50/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 57.86% | -9.19% | 18.18% | 44/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 48.96% | 2% | -12.76% | 57/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 56.12% | 2.09% | -19.82% | 54/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 69.99% | 2% | 9.85% | 16/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 63.72% | 2% | 15.91% | 24/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 54.97% | -3.32% | -3.32% | 39/159 | 48.19% | 退市金泰 | 95.93% | 行业排名> |
| 2015-12-31 | 56.86% | 1.98% | 1.98% | 30/159 | 45.97% | 贝达药业 | 95.58% | 行业排名> |